Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Clive Wood, PhD

Frontiers of Immunotherapy

Boehringer Ingelheim

Ton Schumacher, PhD

T cell Recognition in Human Cancer

Netherlands Cancer Institute

Paul Parren, PhD

How Antibodies Trigger Cytotoxicity?

Leiden University Medical Center

Andrew Bradbury, MD, PhD

The Impact of Next Generation Sequencing on Antibody Selection and Engineering

Specifica

07:30 - 08:25

Registration, Coffee and Exhibit/Poster Viewing

More
08:25 - 08:30
Chairperson's Remarks

Chairperson's Remarks

  • Matthias Peipp, PhD - Professor and Head of Research, Christian-Albrechts-University Kiel
More
Showing of Streams
Showing of Streams
12:20 - 13:30

Networking Lunch and Exhibit/Poster Viewing

More
Showing of Streams
Showing of Streams
17:45 - 18:45

Networking Cocktail Reception and Exhibit/Poster Viewing

More
07:30 - 08:25 55 mins
Registration, Coffee and Exhibit/Poster Viewing
08:25 - 08:30 5 mins
Chairperson's Remarks
  • Matthias Peipp, PhD - Professor and Head of Research, Christian-Albrechts-University Kiel
08:30 - 09:05 35 mins
Info
Keynote Presentations
Frontiers of Immunotherapy
  • Keynote Presenter Clive Wood, PhD - Corporate Senior Vice President, Global Head of Discovery Research, Boehringer Ingelheim

As our understanding of the molecular and cellular control of the immune system has grown, we have exploited this knowledge to bring about major advances in human health. Immunology has furnished both the tools, often in the form of monoclonal antibodies, as well as the insights in to disease mechanisms that have created breakthroughs in multiple therapeutic areas. The pace of this innovation continues to grow as exemplified by checkpoint inhibitors and engineered T-cell therapeutics. Examples of the next advances in immunotherapy will be discussed with an emphasis on treatments for autoimmune diseases and cancer.

09:05 - 09:10 5 mins
Keynote Presentations
Keynote Questions
09:10 - 09:45 35 mins
Info
Keynote Presentations
T cell Recognition in Human Cancer
  • Keynote Presenter Ton Schumacher, PhD - Professor and Group Leader, Division of Immunology, Netherlands Cancer Institute

The central ambition of our work is to determine which factors limit the ability of T cells to control human cancers, with the ultimate aim to overcome these barriers. Using assays of human tumour material we are determining how the differentiation state of intratumoral T cells can help predict therapy outcome. Furthermore, using genetic screening systems, we are identifying novel regulators of the immune checkpoints that control the activity of such intratumoral T cells. Collectively, this work is expected to yield novel therapeutic leads and improved biomarkers that may be used for patient stratification.

09:45 - 09:50 5 mins
Keynote Presentations
Keynote Questions
09:50 - 10:30 40 mins
Keynote Presentations
Networking Refreshment Break and Exhibit/Poster Viewing
10:30 - 11:05 35 mins
Info
Keynote Presentations
How Antibodies Trigger Cytotoxicity?
  • Keynote Presenter Paul Parren, PhD - Professor, Department of Immunohematology and Blood Transfusion, Leiden University Medical Center

Antibodies are the gatekeepers of our immune system. They latch on to cells or antigens recognised as foreign in a highly specific manner and mark them for killing and/or destruction. In immunotherapy, we have learned to exploit these unique qualities of antibodies for the generation of a myriad of successful drugs in a wide range of therapeutic indications. In this keynote lecture I will discuss how antibodies may induce cell killing, varying from recent insights into the mechanism of complement activation to the use of antibody-conjugates to deliver cytotoxic drugs.

11:05 - 11:10 5 mins
Keynote Presentations
Keynote Questions
11:10 - 11:45 35 mins
Keynote Presentations
The Impact of Next Generation Sequencing on Antibody Selection and Engineering
  • Keynote Presenter Andrew Bradbury, MD, PhD - Chief Scientific Officer, Specifica
11:45 - 11:50 5 mins
Keynote Presentations
Keynote Questions
11:50 - 12:20 30 mins
Info
Scientific Briefing
Affinity Measurements: Ask the Right Question and Choose the Right Technology to Have an Unbiased Answer
  • Palaniswami Rathanaswami, PhD - Senior Scientist, Biologics Discovery, Amgen, Inc.

Generation of high affinity antibodies is a design goal for many therapeutic programs. A number of technologies and instruments are available for measuring antibody affinities.  Each one has its own merits and demerits, depending on the sensitivity and throughput requirements as well as whether the target is soluble or membrane expressed which will be discussed in the presentation. 


12:20 - 13:30 70 mins
Networking Lunch and Exhibit/Poster Viewing
13:30 - 14:00 30 mins
Info
Track 2: Scientific Briefing
Challenges and Opportunities in Early Stage Antibody Drug Discovery
  • David Matthews, PhD - Head of BioTherapeutics, Associate Director, LifeArc

LifeArc's BioTherapeutics group looks to collaborate in the translational drug discovery space between academia and industry. We aim to de-risk targets by developing biologics and validation studies to independently confirm published reports and develop therapeutics. We will discuss some case studies to show, together with our collaborative partners, we have helped develop novel targets to lead therapeutic candidates for indications such as osteoporosis, asthma and dementia.

14:00 - 14:05 5 mins
Track 1: Intractable Targets / Antibody Discovery Technologies
Chairman's Remarks
  • Chairperson John McCafferty, PhD - CEO and Founder, IONTAS
14:00 - 14:05 5 mins
Track 2: Antibody Effector Functions and Novel Formats
Co-Chairs' Remarks
  • Chairperson Jeanette Leusen, PhD - Associate Professor, Head Immunotherapy Group, UMC Utrecht
  • Chairperson Matthias Peipp, PhD - Professor and Head of Research, Christian-Albrechts-University Kiel
14:05 - 14:35 30 mins
Info
Track 1: Intractable Targets / Antibody Discovery Technologies
Immunomodulatory Target Discovery Using Antibody Technologies
  • Pierre-Francois Berne, PhD - Technology Lead, Sanofi R&D

Antibodies able to modulate function of immune cells represent promising assets for prevention and treatment of disease, in particular, for autoimmune disorders and cancer. In this presentation, phenotypic screen approach that yielded antibodies able to restore function of impaired immune cells will be discussed.

14:05 - 14:35 30 mins
Info
Track 2: Antibody Effector Functions and Novel Formats
Mechanisms Underlying Antibody-mediated Complement Activation
  • Piet Gros, PhD - Professor, Chemistry and Biomolecular Sciences, Utrecht University

To understand how antibodies activate the complement system, we studied C1-antibody complexes formed on liposomes and in solution by cryo-EM tomography and single-particle analysis, respectively. The data suggest that complement may be initiated both through proximity of multiple complexes, providing cross-activation of the C1 proteolytic enzymes, and by single isolated complexes through compaction of the C1q arms upon binding to antibody Fc-platforms.

14:35 - 15:05 30 mins
Track 1: Intractable Targets / Antibody Discovery Technologies
High-throughput Single-cell Phenotyping and Sequencing Using Droplet-based Microfuidics for Therapeutic Antibody Discovery
  • Andrew Griffiths, PhD - Professor of Biochemistry, ESPCI
14:35 - 15:05 30 mins
Info
Track 2: Antibody Effector Functions and Novel Formats
Improving Therapeutic Activity of DR5-specific Antibodies by Inducing Hexamer Formation upon Target Binding - A Role for C1q
  • Marije Overdijk, PhD - Senior Scientist, Genmab B.V.

IgG antibodies organise via intermolecular Fc-Fc interactions into ordered hexamers upon cell surface target binding. We identified Fc mutations that enhance antigen-dependent hexamerisation resulting in enhanced complement activation and/or enhanced target clustering, while retaining solution-monomericity and developability characteristics of regular human IgG1 (HexaBody® technology). This technology was applied to two non-competing DR5-specific antibodies. The dual epitope targeting and enhanced antibody hexamerisation by the mixture of these two HexaBody molecules induces potent DR5 agonist activity and tumor cell death through hexamer-induced DR5 clustering, which was enhanced in the presence of C1q.


15:05 - 15:35 30 mins
Info
Track 1: Intractable Targets / Antibody Discovery Technologies
Building a Single Donor Phage Antibody Library with NGS Validation
  • Andrew Bradbury, MD, PhD - Chief Scientific Officer, Specifica

The traditional approach to generating natural phage antibody libraries has been to use as many donors as possible. However, given that naive B cells each have unique antibodies, it may be more important to use as many lymphocytes as possible, even if derived from a single donor. This talk will describe the creation of a highly functional antibody library from a single donor, in which all steps were quality controlled by next generation sequencing.

15:05 - 15:35 30 mins
Track 2: Antibody Effector Functions and Novel Formats
Approaches to Improve Myeloid Effector Cell Recruitment for Tumor Immunotherapy
  • Thomas Valerius, MD - Professor, Faculty of Medicine, University Hospital Schleswig-Holstein
15:35 - 16:15 40 mins
Track 1: Intractable Targets / Antibody Discovery Technologies
Networking Refreshment Break and Exhibit/Poster Viewing
15:35 - 16:15 40 mins
Track 2: Antibody Effector Functions and Novel Formats
Networking Refreshment Break and Exhibit/Poster Viewing
16:15 - 16:45 30 mins
Info
Track 1: Intractable Targets / Antibody Discovery Technologies
Generation of Ion Channel Blocking Antibodies by Fusing Venom-derived "Knottins" into Antibody CDR Loops
  • Aneesh Karatt-Vellatt, PhD - Group Leader, Iontas

Cysteine-knot miniproteins (knottins) have potential as therapeutic agents to block ion channels and GPCRs in cancer, autoimmunity and chronic pain but suffer from manufacturing difficulties, short half-lives and a lack of specificity. Using X-ray crystallography and biochemical assays we have demonstrated that functional knottins can be inserted into peripheral antibody CDRs via short linkers. This approach greatly increases the diversity of these peripheral CDR loops while allowing additional contribution of binding from the remaining CDRs. Thus, the resulting "knotbody" retains the advantage of blocking activity from the knottin while enjoying the extended half-life and additional specificity conferred by the antibody molecule.

16:15 - 16:45 30 mins
Info
Track 2: Antibody Effector Functions and Novel Formats
A Novel FAP-targeted 4-1BB Agonist for Combination Immunotherapy
  • Christian Klein, PhD - Head Oncology Programs, Roche Innovation Center Zurich

Immune co-stimulation via 4-1BB agonism is an important element of next generation CAR-T cell therapy. The clinical development of first generation 4-1BB agonistic antibodies has been hampered by hepatic toxicity. Here we describe a novel tumor targeted 4-1BB agonist for combination with T cell bispecific antibodies which may represent an off-the-shelf alternative to CAR-T cell therapies.

16:45 - 17:15 30 mins
Info
Track 1: Intractable Targets / Antibody Discovery Technologies
Opportunities for Therapeutic Antibodies Directed at G Protein-coupled Receptors and Ion Channels
  • Catherine Hutchings, PhD - Independent Consultant, Independent Consultant

G protein-coupled receptors (GPCRs) and ion channels represent important target classes for therapeutic drug discovery across a wide range of diseases. Progress made with antibody-based therapeutics will be reviewed outlining the breadth and diversity of antibody molecules, target opportunities in the global R&D and the clinical pipeline, as well as the expansion of opportunities afforded by next-generation modalities.

16:45 - 17:15 30 mins
Info
Track 2: Antibody Effector Functions and Novel Formats
Fc Engineering to Enhance Immunostimulatory Antibodies for Cancer Therapy
  • Stephen Beers, PhD - Associate Professor in Cancer Immunology and Immunology, University of Southampton

Clinical results with immunomodulatory mAb have revived the belief that the immune system holds the key to controlling cancer. Here we show that immunostimulatory mAb can deliver therapy through multiple mechanisms in pre-clinical tumour models, and that the mechanism used depends on antigen expression, mAb isotype and FcγR availability. Using this knowledge, we engineered novel agents that were able to more effectively harness these mechanisms and thereby enhance outcome. These data have broad implications for selecting new immune targets, designing combination therapies and engineering mAb.


17:15 - 17:45 30 mins
Info
Track 1: Intractable Targets / Antibody Discovery Technologies
Targeting Challenging Antigens
  • Daniel Christ, PhD - Associate Professor, Director Centre for Targeted Therapy, Garvan Institute of Medical Research

Antibody therapeutics have transformed the treatment of cancer and inflammatory conditions. However, many targets, including carbohydrates and structured nucleic acids, remain challenging. This is exemplified by a failure to develop broad and long-lasting antibodies against influenza and HIV, which are cloaked in self-carbohydrate. Here we describe strategies and mutational trajectories that overcome antibody affinity and specificity limitations.

17:15 - 17:45 30 mins
Info
Track 2: Antibody Effector Functions and Novel Formats
Targeting Immune Regulation at the Tumor Site: Defining the Interplay between Therapy and Tumor Microenvironment
  • Sergio Quezada, PhD - Professorial Research Fellow, UCL Cancer Institute

In recent years, several publications have demonstrated the essential role that the tumor microenvironment and Fc Receptors play for the vivo activity of checkpoint targeting antibodies. In this talk we will discuss novel development in this area relating the mechanism of action and the development of immune modulatory antibodies and combinations that promote intra-tumoural Treg with maximal modulatory activity.

17:45 - 18:45 60 mins
Networking Cocktail Reception and Exhibit/Poster Viewing